Annual Report 2002–03

(左起）余仁生集團黃雪英女士和余義明先生、工商及科技局常任秘 書長（通訊及科技）何宣威先生，以及中大梁秉中敎授和陳小章敎授 公布有關白鳳丸的研究成果。 A press conference to release findings of a research on Bak Foong Pills. From left: Ms. Wong Suet-ying and Mr. Richard Eu of Eu Yang Sang, Mr. Francis Ho, Permanent Secretary for Commerce, Industry and Technology (Communications and Technology), and Prof. P.C. Leung and Prof. Chan Hsiao-chang of the University. Menoease 5 .傳統中藥現代化 香港創新及科技基金與余仁生（香港）有限公 司於二零零零年六月合資九百二十八萬港元， 資助本校硏究「白鳳丸」成效的藥理機制。硏 究由上皮細胞生物學硏究中心負責，除為「白 鳳丸」建立了藥理基礎外，更提出治療更年期 綜合症的新配方。這配方能調節老年動物體內 的雌激素分泌，抗高血壓，以及修復免疫系統 的失衡。這項硏究印證了「白鳳丸」的藥效， 並開發了針對更年期婦女的保健產品「延彩白 鳳丸」。 invention was licensed to a local health supplement manufacturer, who employed Dr. Kevin Chu as its R&D Manager. Oncozac, a commercial product based on the proprietary extraction method, has been launched in the market. 5. Modernization of Traditional Chinese Medicine In June 2000, the Innovation and Technology Fund and Eu Yan Sang (Hong Kong) Ltd. provided the University with HK$9.28 million to conduct a three-year research on the pharmacological mechanisms underlying the beneficial effects of Bak Foong Pills (BFP), a well- known Chinese healthcare product based on a century-old formula. The project was undertaken by the University's Epithelial Cell Biology Research Centre, who produced a modified formula that has effects on oestrogenic activity and hormonal profile, anti-hypertension, and the restoration of immune imbalance in aging animals. The project confirmed the beneficial effects of BFP, and led to the development of a new formula with specific effects on menopausal syndromes, which has been launched in the market as Menoease. 5 2 香港中文大學年報 CUHK Annual Report 2002-2003